Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Cetuximab with Chemoradiation in Locally Advanced Esophageal Squamous Cell Carcinoma
NCT04229459Phase 2Active, not recruiting
- Start
- Feb 2020
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, KL-140 in Esophageal Squamous Cell Carcinoma (ESCC). Started Feb 2020; status: active, not recruiting.
02
Drugs
nivolumabKL-140
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04229459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04229459.